Related references
Note: Only part of the references are listed.Ring closure strategy leads to potent RIPK3 inhibitors
Shuwei Wu et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2021)
Small-Molecule Inhibitors of Necroptosis: Current Status and Perspectives
Chunlin Zhuang et al.
JOURNAL OF MEDICINAL CHEMISTRY (2020)
Mutations that prevent caspase cleavage of RIPK1 cause autoinflammatory disease
Najoua Lalaoui et al.
NATURE (2020)
A dominant autoinflammatory disease caused by non-cleavable variants of RIPK1
Panfeng Tao et al.
NATURE (2020)
Discovery of a Potent RIPK3 Inhibitor for the Amelioration of Necroptosis-Associated Inflammatory Injury
Kaijiang Xia et al.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY (2020)
Targeting RIPK1 for the treatment of human diseases
Alexei Degterev et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2019)
Identification of a RIP1 Kinase Inhibitor Clinical Candidate (GSK3145095) for the Treatment of Pancreatic Cancer
Philip A. Harris et al.
ACS MEDICINAL CHEMISTRY LETTERS (2019)
Highly Selective Inhibition of Tyrosine Kinase 2 (TYK2) for the Treatment of Autoimmune Diseases: Discovery of the Allosteric Inhibitor BMS-986165
Stephen T. Wrobleski et al.
JOURNAL OF MEDICINAL CHEMISTRY (2019)
Discovery of potent necroptosis inhibitors targeting RIPK1 kinase activity for the treatment of inflammatory disorder and cancer metastasis
Jue Hou et al.
CELL DEATH & DISEASE (2019)
Lipophilic Efficiency as an Important Metric in Drug Design
Ted W. Johnson et al.
JOURNAL OF MEDICINAL CHEMISTRY (2018)
Ubiquitin-Mediated Regulation of RIPK1 Kinase Activity Independent of IKK and MK2
Alessandro Annibaldi et al.
MOLECULAR CELL (2018)
RIP kinases as modulators of inflammation and immunity
Sudan He et al.
NATURE IMMUNOLOGY (2018)
Discovery of a First-in-Class Receptor Interacting Protein 1 (RIP1) Kinase Specific Clinical Candidate (GSK2982772) for the Treatment of Inflammatory Diseases
Philip A. Harris et al.
JOURNAL OF MEDICINAL CHEMISTRY (2017)
RIPK1 mediates a disease-associated microglial response in Alzheimer's disease
Dimitry Ofengeim et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2017)
Design, Synthesis, and Structure Activity Relationship of Tetrahydropyrido[4,3-d]pyrimidine Derivatives as Potent Smoothened Antagonists with in Vivo Activity
Wenfeng Lu et al.
ACS CHEMICAL NEUROSCIENCE (2017)
RIPK1 and RIPK3 Kinases Promote Cell-Death-Independent Inflammation by Toll-like Receptor 4
Malek Najjar et al.
IMMUNITY (2016)
Discovery of the Potent and Selective M1 PAM-Agonist N-[(3R,4S)-3-Hydroxytetrahydro-2H-pyran-4-yl]-5-methyl-4-[4-(1,3-thiazol-4-yl)benzyl]pyridine-2-carboxamide (PF-06767832): Evaluation of Efficacy and Cholinergic Side Effects
Jennifer E. Davoren et al.
JOURNAL OF MEDICINAL CHEMISTRY (2016)
DNA-Encoded Library Screening Identifies Benzo[b][1,4]oxazepin-4-ones as Highly Potent and Monoselective Receptor Interacting Protein 1 Kinase Inhibitors
Philip A. Harris et al.
JOURNAL OF MEDICINAL CHEMISTRY (2016)
RIPK1 inhibits ZBP1-driven necroptosis during development
Kim Newton et al.
NATURE (2016)
In Vitro Metabolic Stability and Permeability of Gymnemagenin and Its In Vivo Pharmacokinetic Correlation in Rats - A Pilot Study
Rammohan Bera et al.
PLANTA MEDICA (2016)
Evaluation of the inhibition potential of plumbagin against cytochrome P450 using LC-MS/MS and cocktail approach
Ang Chen et al.
SCIENTIFIC REPORTS (2016)
NF-κB-Independent Role of IKKα/IKKβ in Preventing RIPK1 Kinase-Dependent Apoptotic and Necroptotic Cell Death during TNF Signaling
Yves Dondelinger et al.
MOLECULAR CELL (2015)
Cutting Edge: RIP1 Kinase Activity Is Dispensable for Normal Development but Is a Key Regulator of Inflammation in SHARPIN-Deficient Mice
Scott B. Berger et al.
JOURNAL OF IMMUNOLOGY (2014)
Triazolopyridines as Selective JAK1 Inhibitors: From Hit Identification to GLPG0634
Christel J. Menet et al.
JOURNAL OF MEDICINAL CHEMISTRY (2014)
RIPK1 maintains epithelial homeostasis by inhibiting apoptosis and necroptosis
Marius Dannappel et al.
NATURE (2014)
Regulation of RIP1 kinase signalling at the crossroads of inflammation and cell death
Dimitry Ofengeim et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2013)
Structural Basis of RIP1 Inhibition by Necrostatins
Tian Xie et al.
STRUCTURE (2013)
TRAIL induces necroptosis involving RIPK1/RIPK3-dependent PARP-1 activation
S. Jouan-Lanhouet et al.
CELL DEATH AND DIFFERENTIATION (2012)
Mitigating Heterocycle Metabolism in Drug Discovery
David J. St Jean et al.
JOURNAL OF MEDICINAL CHEMISTRY (2012)
Necrostatin-1 analogues: critical issues on the specificity, activity and in vivo use in experimental disease models
N. Takahashi et al.
CELL DEATH & DISEASE (2012)
Metabolism-Directed Design of Oxetane-Containing Arylsulfonamide Derivatives as γ-Secretase Inhibitors
Antonia F. Stepan et al.
JOURNAL OF MEDICINAL CHEMISTRY (2011)
THE DUAL FUNCTIONS OF RECEPTOR INTERACTING PROTEIN 1 IN FAS-INDUCED HEPATOCYTE DEATH DURING SEPSIS
Sam I. McNeal et al.
SHOCK (2011)
Phosphorylation-Driven Assembly of the RIP1-RIP3 Complex Regulates Programmed Necrosis and Virus-Induced Inflammation
YoungSik Cho et al.
CELL (2009)
Receptor Interacting Protein Kinase-3 Determines Cellular Necrotic Response to TNF-α
Sudan He et al.
CELL (2009)
Necroptosis: A Specialized Pathway of Programmed Necrosis
Lorenzo Galluzzi et al.
CELL (2008)
High-throughput screening of protein binding by equilibrium dialysis combined with liquid chromatography and mass spectrometry
H Wan et al.
JOURNAL OF CHROMATOGRAPHY A (2006)
Chemical inhibitor of nonapoptotic cell death with therapeutic potential for ischemic brain injury
A Degterev et al.
NATURE CHEMICAL BIOLOGY (2005)
Share Paper
